were stimulated on the same day of isolation. Both moDCs and mDCs were pre-treated with Tofacitinib and then stimulated with either lipopolysaccharide (LPS) or combination of LPS with IFN-γ for 4 hours. Cytokines were measured using enzyme-linked immunosorbent assay (ELISA) and gene expression was assessed using quantitative polymerase chain reaction (qPCR).

**Results:** Treatment of both mDCs and moDCs with Tofacitinib led to a decreased mRNA expression of IL-12 p40 (IL12B) in the presence of LTR4 and IFN-γ co-stimulation. The decreased IL12B mRNA expression also resulted in lower production of IL-12 p40 and IL-23 proteins in mDCs.

**Conclusion:** In this work, we demonstrated for the first time that Tofacitinib can suppress the production of IL-23/IL-12 p40 subunit in mDCs, upon the condition that an active type II IFN signalling is also present in these cells. This observation indicates that specific factors, such as endogenous IFN-γ levels in the serum of PsA patients, can possibly predict differential responses to Tofacitinib treatment.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3307

---

**Table 1. Evolution of cartilage changes, walking speed and serum C-terminal telopeptide of type II collagen (CTX-II) concentrations in wild-type C57BL/6 male mice.**

<table>
<thead>
<tr>
<th>Age</th>
<th>New-born</th>
<th>1 week</th>
<th>1 month</th>
<th>3 months</th>
<th>6 months</th>
<th>9 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CTX-II concen-trations (pg/ml)</strong></td>
<td><strong>0.0 (0.0)</strong></td>
<td><strong>0.0 (0.0)</strong></td>
<td><strong>0.2 (0.3)</strong></td>
<td><strong>1.3 (0.6)</strong>*</td>
<td><strong>3.3 (0.6)</strong>*</td>
<td><strong>3.7 (0.6)</strong></td>
<td><strong>4.3 (0.6)</strong>*</td>
</tr>
<tr>
<td><strong>OARSI score (0 to 6)</strong></td>
<td><strong>1.0 (1.0)</strong></td>
<td><strong>1.1 (1.0)</strong></td>
<td><strong>4.0 (3.8)</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
</tr>
<tr>
<td><strong>Walking speed (cm.s-1)</strong></td>
<td><strong>10.5 (1.5)</strong></td>
<td><strong>11.3 (4.3)</strong></td>
<td><strong>11.4 (1.8)</strong></td>
<td><strong>3.2 (0.8)</strong>*</td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
</tr>
</tbody>
</table>

N ≥ 3 per timepoint. All results are means (standard deviation). *p<0.05 as compared to the previous timepoint using the non-parametric Mann-Whitney U-test.

---

**Figure 1.** (A) New born, 1-week- and 1-, 3-, 6-, 9- and 12-month-old wild-type C57BL/6 male mice (N=3 per timepoint) were evaluated for cartilage changes following OARSI recommended guidelines by 3 independent readers. Each point represents the mean of OARSI score per mice scored by 3 independent readers. (B) 1-, 3-, 6- and 9-month-old wild-type C57BL/6 male mice were evaluated for walking speed using the LocoTronic® system. Each point represents the mean of 3 measures of walking speed per mice. All results are means (SD). *p<0.05 as compared to the previous timepoint using the non-parametric Mann-Whitney U-test.

**Disclosure of Interests:** Joulair Akoum: None declared, Khadja Tahiri: None declared, François Etienne: None declared, Marie-Thérèse Corvol: None declared, François Rannou Grant/research support from: Pierre Fabre, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Fondation Arthritis, Consultant of: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Speakers bureau: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Christelle Nguyen: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5989

---

**Figure 1A.** A. New born, 1-week- and 1-, 3-, 6-, 9- and 12-month-old wild-type C57BL/6 male mice. B. 1-, 3-, 6- and 9-month-old wild-type C57BL/6 male mice were evaluated for walking speed using the LocoTronic® system. Each point represents the mean of 3 measures of walking speed per mice. All results are means (SD). *p<0.05 as compared to the previous timepoint using the non-parametric Mann-Whitney U-test.

**Disclosure of Interests:** Joulair Akoum: None declared, Khadja Tahiri: None declared, François Etienne: None declared, Marie-Thérèse Corvol: None declared, François Rannou Grant/research support from: Pierre Fabre, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Fondation Arthritis, Consultant of: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Speakers bureau: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Christelle Nguyen: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5989

---

**Table 1. Evolution of cartilage changes, walking speed and serum C-terminal telopeptide of type II collagen (CTX-II) concentrations in wild-type C57BL/6 male mice.**

**Age** | **New-born** | **1 week** | **1 month** | **3 months** | **6 months** | **9 months** | **12 months**
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CTX-II concentrations (pg/ml)</strong></td>
<td><strong>0.0 (0.0)</strong></td>
<td><strong>0.0 (0.0)</strong></td>
<td><strong>0.2 (0.3)</strong></td>
<td><strong>1.3 (0.6)</strong>*</td>
<td><strong>3.3 (0.6)</strong>*</td>
<td><strong>3.7 (0.6)</strong></td>
<td><strong>4.3 (0.6)</strong>*</td>
</tr>
<tr>
<td><strong>OARSI score (0 to 6)</strong></td>
<td><strong>1.0 (1.0)</strong></td>
<td><strong>1.1 (1.0)</strong></td>
<td><strong>4.0 (3.8)</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
</tr>
<tr>
<td><strong>Walking speed (cm.s-1)</strong></td>
<td><strong>10.5 (1.5)</strong></td>
<td><strong>11.3 (4.3)</strong></td>
<td><strong>11.4 (1.8)</strong></td>
<td><strong>3.2 (0.8)</strong>*</td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
<td><strong>-</strong></td>
</tr>
</tbody>
</table>

N ≥ 3 per timepoint. All results are means (standard deviation). *p<0.05 as compared to the previous timepoint using the non-parametric Mann-Whitney U-test.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5989

---

**Figure 1A.** A. New born, 1-week- and 1-, 3-, 6-, 9- and 12-month-old wild-type C57BL/6 male mice (N=3 per timepoint) were evaluated for cartilage changes following OARSI recommended guidelines by 3 independent readers. Each point represents the mean of OARSI score per mice scored by 3 independent readers. (B) 1-, 3-, 6- and 9-month-old wild-type C57BL/6 male mice were evaluated for walking speed using the LocoTronic® system. Each point represents the mean of 3 measures of walking speed per mice. All results are means (SD). *p<0.05 as compared to the previous timepoint using the non-parametric Mann-Whitney U-test.

**Disclosure of Interests:** Joulair Akoum: None declared, Khadja Tahiri: None declared, François Etienne: None declared, Marie-Thérèse Corvol: None declared, François Rannou Grant/research support from: Pierre Fabre, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Fondation Arthritis, Consultant of: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Genévrier, Speakers bureau: Pierre Fabre, Fidia, MSD, Pfizer, Bone Therapeutics, Expanscience, Grunenthal, Thuasne, Christelle Nguyen: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5989